3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Moderate Hepatic Impairment
1
Meningioma
1
Lymphoma
1
Lung Neoplasms
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Interventions
ribociclib
1
palbociclib
1
capivasertib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Locally Advanced (Inoperable) or Metastatic Breast Cancer
×
capivasertib
×
30 days
×
Clear all
NCT04862663
2026-05-27
CAPItello-292
AstraZeneca
Phase 3
Recruiting
895 enrolled